Alembic Pharma gets USFDA EIR for Oncology Injectable Formulation Facility at Panelav

Published On 2022-12-10 05:48 GMT   |   Update On 2022-12-10 05:48 GMT
Advertisement

Vadodara: Drugmaker Alembic Pharma has recently announced that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its Oncology Injectable Formulation Facility at Panelav.

The facility was inspected from 4 th October, 2022 to 14th October, 2022.

"This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our Oncology Injectable Formulation Facility at Panelav during the period from 4th October, 2022 to 14th October, 2022," Alembic Pharma stated in a BSE filing.

Advertisement
"This was preapproval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA. The Company had also started receiving ANDA approval manufactured at this facility," the company further stated.

Read also: Alembic Pharma osteoarthritis drug gets USFDA okay

Medical Dialogues had earlier reported that the United States Food and Drug Administration (USFDA) had issued a Form 483 with 4 procedural observations after an inspection of the Panelav facility. An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Read also: Alembic Pharma Panelav facility gets 4 USFDA observations

Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Gujarat. It is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Products under International Generics are manufactured across our world-class facilities in Panelav, Karkhadi, and Jarod in Gujarat. Under this vertical, the company also has R&D facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (USA).

Read also: Alembic Pharma bags USFDA nod for Hypertension drug Nifedipine Extended Release

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News